← All indications
Dwarfism
A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.
Subtype terms (8)
More specific conditions that are subtypes of Dwarfism in the MeSH hierarchy.
- Achondroplasia
10 drugs (5 approved, 5 experimental)
- Cockayne Syndrome
1 drug approved
- Congenital Hypothyroidism
2 drugs (1 approved, 1 experimental)
- Dwarfism, Pituitary
12 drugs (9 approved, 3 experimental)
- Laron Syndrome
1 drug approved
- Mulibrey Nanism
- Silver-Russell Syndrome
1 drug approved
- Weill-Marchesani Syndrome
Drugs by status
Approved for this indication (3)
Phase 2 trials (3)
Organizations
Organization Involved with Phase 4 Indications (13)
Organization Involved with Phase 3 Indications (33)
- AstraZeneca
- Merck
- Novo Nordisk
- Eli Lilly
- Genentech
- Novartis
- Dong-A Pharmaceutical
- Huazhong University of Science and Technology
- Ajou University
- Korea University
- Maimonides Medical Center
- Seoul National University
- Shengjing Hospital
- Thomas Jefferson University
- Yonsei University
- Capital Medical University
- Chonbuk National University
- Chongqing Medical University
- Fudan University
- Peking University
- Zhengzhou University
- University of Ulsan
- Uppsala University
- Jiao Tong University
- Catholic University of Korea
- University of Sao Paulo
- University of Gothenburg
- Kyungpook University
- Thrasher Research Fund
- Chonnam National University
- +3 more
Organization Involved with Phase 2 Indications (7)
Organization Involved with Other Experimental Indications (3)